Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14993156 | 0.80 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL7152047 | 0.76 | TRPV1 (0.30) | TRPV1 | |
| SCHEMBL14993445 | 0.76 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL8886309 | 0.72 | TRPV1 (0.44) | TRPV1 | |
| SCHEMBL1674776 | 0.72 | TRPV1 (0.32) | TRPV1 | |
| SCHEMBL13674526 | 0.69 | TRPV1 (0.74) | TRPV1 | |
| SCHEMBL1496194 | 0.69 | — | — | |
| SCHEMBL15617433 | 0.68 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL27946327 | 0.67 | ALDH1A1 (0.38) | TRPV1 | |
| SCHEMBL4572700 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005947-B2 | Modified hydrocarbon resins as fluid loss additives | INGEVITY SOUTH CAROLINA, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3071782-A1 | MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES | Georgia-Pacific Chemicals LLC (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077215-A1 | MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES | GEORGIA-PACIFIC CHEMICALS LLC (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150136402-A1 | MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES | GEORGIA-PACIFIC CHEMICALS LLC (US) | 2015-05-21 | — | — | US | disclosed |
| US-8404869-B2 | Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome | MAZENCE INC. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | YUNGJIN PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| EP-2137175-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | Mazence Inc. (KR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008133441-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2008-11-06 | — | — | WO | disclosed |
| US-4433100-A | DICYCLOPENTADIENE, NON-AROMATIC UNSATURATED HYDROCARBON, FATTY OR ROSIN ACID | NEVILLE CHEMICAL COMPANY (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | CYP27A1, CYP46A1, PCSK9 | TRPV1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.